These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29246734)

  • 1. Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.
    Liu RSC; Olkhov-Mitsel E; Jeyapala R; Zhao F; Commisso K; Klotz L; Loblaw A; Liu SK; Vesprini D; Fleshner NE; Bapat B
    J Urol; 2018 Jun; 199(6):1475-1481. PubMed ID: 29246734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.
    Zhao F; Vesprini D; Liu RSC; Olkhov-Mitsel E; Klotz LH; Loblaw A; Liu SK; Bapat B
    Urol Oncol; 2019 May; 37(5):297.e9-297.e17. PubMed ID: 30777394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
    Zhao F; Olkhov-Mitsel E; van der Kwast T; Sykes J; Zdravic D; Venkateswaran V; Zlotta AR; Loblaw A; Fleshner NE; Klotz L; Vesprini D; Bapat B
    J Urol; 2017 Feb; 197(2):335-341. PubMed ID: 27545574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.
    Basourakos SP; Davis JW; Chapin BF; Ward JF; Pettaway CA; Pisters LL; Navai N; Achim MF; Wang X; Chen HC; Choi S; Kuban D; Troncoso P; Hanash S; Thompson TC; Kim J
    BJU Int; 2018 Jan; 121(1):69-76. PubMed ID: 28710901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.
    Xu L; Mao X; Grey A; Scandura G; Guo T; Burke E; Marzec J; Abdu S; Stankiewicz E; Davies CR; Rajan P; Tipples K; Hines J; Chan PY; Campbell D; Wilkinson K; Kudahetti S; Shamash J; Oliver T; Berney D; Shaw G; Lu YJ
    J Urol; 2020 Jan; 203(1):73-82. PubMed ID: 31389764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
    Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
    J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
    Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
    Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
    Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
    Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Value of Circulating miR-324 for Prostate Cancer.
    Jin YY; Tong SQ; Tong M
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.
    McDonald AC; Vira M; Walter V; Shen J; Raman JD; Sanda MG; Patil D; Taioli E
    Prostate; 2019 Jun; 79(9):961-968. PubMed ID: 30958910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL.
    Fujizuka Y; Ito K; Oki R; Suzuki R; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
    Int J Urol; 2017 Aug; 24(8):602-609. PubMed ID: 28560739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    Adamy A; Yee DS; Matsushita K; Maschino A; Cronin A; Vickers A; Guillonneau B; Scardino PT; Eastham JA
    J Urol; 2011 Feb; 185(2):477-82. PubMed ID: 21167529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.
    Felker ER; Wu J; Natarajan S; Margolis DJ; Raman SS; Huang J; Dorey F; Marks LS
    J Urol; 2016 May; 195(5):1421-1427. PubMed ID: 26674305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
    Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
    J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.